What drove ALNEV.PA stock lower pre-market today?

The pre-market drop to **EUR 0.0013** (-13.33%) was driven by heavy selling and elevated volume of **19,674,747** shares. No single public catalyst was confirmed; market participants cite funding and trial-risk sensitivity typical for small biotech names.

How does Meyka AI rate ALNEV.PA and what does that mean?

Meyka AI rates ALNEV.PA **62.14/100 (Grade B: HOLD)**. The grade blends benchmark, sector, growth, metrics and forecasts. It is informational only and not investment advice; investors should run independent due diligence.

What are realistic price targets for ALNEV.PA stock?

Near-term technical bounce target: **EUR 0.0020** (+53.85%). Conservative downside: **EUR 0.0010** (-23.08%). A scenario-driven 12-month target is **EUR 0.05**, conditional on positive clinical or funding news.

What key metrics should investors watch for ALNEV.PA?

Watch cash per share (**EUR 2.50**), EPS (**-221.36**), share count (**476,625**), and any planned capital raises. Clinical trial updates and regulatory milestones will be the main catalysts for price movement.

EU Stocks

ALNEV.PA Neovacs S.A. EURONEXT -13.33% pre-market 06 Mar 2026: key risk signs

ByHuzaifa Zahoor March 6, 2026

The ALNEV.PA stock opened the EURONEXT pre-market session at EUR 0.0014 and is trading at EUR 0.0013, down -13.33% as of 06 Mar 2026. Heavy turnover is visible with 19,674,747 shares traded today versus an average of 11,663,971. The drop places Neovacs S.A. among the top losers in Europe’s healthcare names this morning and raises fresh liquidity and valuation questions for investors watching a biotech with a small market cap and negative EPS.